

Amendments to the Specification

Please replace the paragraph beginning at page 76, line 5 of the specification with the following paragraph:

In summary, on the basis of the data presented in the above examples, 26 CTL candidate peptide epitopes derived from conserved regions of the HCV virus have been identified (Table XXXVIa). These include twelve HLA-A2 supermotif-bearing epitopes, eight HLA-A3 supermotif-bearing epitopes, and one HLA-B7 supermotif-bearing epitopes, each capable of binding to multiple A2-, A3-, or B7-supertype molecules, and immunogenic in HLA transgenic mice or antigenic for human PBL (with the exception of peptide 29.0035/1260.04). Additional epitopes not evaluated for immunogenicity are also included. They are an additional B7-supermotif-bearing epitope and two HLA-A1 and one HLA-A24 high-affinity binding peptides. A known HLA-A31 restricted epitope (VGIYLLPNR (SEQ ID NO: 2472)), which also binds HLA-A33, is set out in Table XXXVIa and is useful in combination with other Class I or Class II epitopes.

Please replace pages 103, 104, 122-125, 127, 131-135, 137-140, 142-163, 165-176a, 177-183, 185, 187-189, 191-194, 198, 199, and 201-204 with the attached pages 103, 104, 122-125, 127, 131-135, 137-140, 142-163, 165-176a, 177-183, 185, 187-189, 191-194, 198, 199, and 201-204.

Attachments:

Exhibit A: Replacement pages 103, 104, 122-125, 127, 131-135, 137-140, 142-163, 165-176a, 177-183, 185, 187-189, 191-194, 198, 199, and 201-204.

Exhibit B: Transaction History of Appl. No. 09/357,757.